RCUS

Arcus Biosciences, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.44
52-Week Range: $13.61 – $31.74
Market Cap: $3.16B
P/E (TTM): —
EPS (TTM): -3.91
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.79
PEG Ratio: —
Return on Equity: -90.82%
Return on Assets: -30.39%
Gross Margin: 0.00%
Operating Margin: -234.15%
Profit Margin: 0.00%
Current Ratio: 3.82
Debt/Equity: 0.51
Total Debt: $238.00M
Free Cash Flow: $-270.62M
Revenue Growth: -74.40%
Earnings Growth: —
Enterprise Value: $2.65B

RCUS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$112.00M	$117.00M	$258.00M	$247.00M
Research & Development	$288.00M	$340.00M	$448.00M	$523.00M
Selling, General & Admin	$104.00M	$117.00M	$120.00M	$110.00M
Operating Expenses	$392.00M	$457.00M	$568.00M	$633.00M
Operating Income	-$280.00M	-$340.00M	-$310.00M	-$386.00M
EBITDA	-$258.00M	-$291.00M	-$268.00M	-$335.00M
Pretax Income	-$266.00M	-$301.00M	-$282.00M	-$353.00M
Income Tax	$1.00M	$6.00M	$1.00M	$0.00
Net Income	-$267.00M	-$307.00M	-$283.00M	-$353.00M
Diluted EPS	-3.71	-4.15	-3.14	-3.29
Diluted Shares	72.00M	74.00M	90.10M	107.40M

RCUS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$206.00M	$127.00M	$150.00M	$222.00M
Receivables	$43.00M	$42.00M	$25.00M	$16.00M
Current Assets	$1.07B	$831.00M	$1.02B	$1.01B
Total Assets	$1.34B	$1.09B	$1.15B	$1.14B
Current Liabilities	$193.00M	$184.00M	$226.00M	$231.00M
Long-Term Debt	—	—	$48.00M	$99.00M
Total Debt	$3.00M	$11.00M	$60.00M	$112.00M
Total Liabilities	$688.00M	$633.00M	$665.00M	$508.00M
Retained Earnings	-$542.00M	-$849.00M	-$1.13B	-$1.49B
Shareholders' Equity	$657.00M	$462.00M	$485.00M	$631.00M
Working Capital	$874.00M	$647.00M	$790.00M	$776.00M

RCUS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$438.00M	-$306.00M	-$170.00M	-$482.00M
Capital Expenditure	-$6.00M	-$24.00M	-$6.00M	-$2.00M
Free Cash Flow	$432.00M	-$330.00M	-$176.00M	-$484.00M
Depreciation & Amortisation	$6.00M	$8.00M	$10.00M	$10.00M
Stock-Based Compensation	$65.00M	$73.00M	$76.00M	$60.00M
Investing Cash Flow	-$413.00M	$194.00M	-$84.00M	$66.00M
Financing Cash Flow	$33.00M	$33.00M	$277.00M	$488.00M
Net Change in Cash	$58.00M	-$79.00M	$23.00M	$72.00M

RCUS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$28.00M	$160.00M	$26.00M	$33.00M	$17.00M	$41.00M
Research & Development	$122.00M	$139.00M	$141.00M	$121.00M	$122.00M	$113.00M
Selling, General & Admin	$28.00M	$29.00M	$27.00M	$26.00M	$29.00M	$24.00M
Operating Expenses	$150.00M	$168.00M	$168.00M	$147.00M	$151.00M	$137.00M
Operating Income	-$122.00M	-$8.00M	-$142.00M	-$114.00M	-$134.00M	-$96.00M
EBITDA	-$108.00M	$4.00M	-$130.00M	-$101.00M	-$123.00M	-$85.00M
Pretax Income	-$112.00M	$0.00	-$135.00M	-$106.00M	-$128.00M	-$91.00M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$112.00M	$0.00	-$135.00M	-$106.00M	-$128.00M	-$91.00M
Diluted EPS	-1.14	0.00	-1.27	-0.89	-1.02	-0.72
Diluted Shares	98.40M	106.50M	106.50M	118.50M	125.40M	126.10M

RCUS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$192.00M	$248.00M	$238.00M	$222.00M	$201.00M	$150.00M
Receivables	$21.00M	$20.00M	$14.00M	$16.00M	$7.00M	$41.00M
Current Assets	$1.03B	$946.00M	$857.00M	$1.01B	$844.00M	$756.00M
Total Assets	$1.16B	$1.07B	$974.00M	$1.14B	$997.00M	$924.00M
Current Liabilities	$192.00M	$210.00M	$235.00M	$231.00M	$209.00M	$198.00M
Long-Term Debt	$48.00M	$97.00M	$98.00M	$99.00M	$100.00M	$101.00M
Total Debt	$60.00M	$109.00M	$111.00M	$112.00M	$113.00M	$114.00M
Total Liabilities	$625.00M	$526.00M	$538.00M	$508.00M	$473.00M	$460.00M
Retained Earnings	-$1.24B	-$1.24B	-$1.38B	-$1.49B	-$1.61B	-$1.70B
Shareholders' Equity	$531.00M	$549.00M	$436.00M	$631.00M	$524.00M	$464.00M
Working Capital	$839.00M	$736.00M	$622.00M	$776.00M	$635.00M	$558.00M

RCUS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$132.00M	-$133.00M	-$97.00M	-$120.00M	-$138.00M	-$119.00M
Capital Expenditure	-$1.00M	—	—	-$1.00M	—	—
Free Cash Flow	-$133.00M	-$133.00M	-$97.00M	-$121.00M	-$138.00M	-$119.00M
Depreciation & Amortisation	$3.00M	$2.00M	$2.00M	$3.00M	$2.00M	$3.00M
Stock-Based Compensation	$16.00M	$15.00M	$14.00M	$15.00M	$19.00M	$15.00M
Investing Cash Flow	$32.00M	$137.00M	$79.00M	-$182.00M	$114.00M	$52.00M
Financing Cash Flow	$142.00M	$52.00M	$8.00M	$286.00M	$3.00M	$16.00M
Net Change in Cash	$42.00M	$56.00M	-$10.00M	-$16.00M	-$21.00M	-$51.00M

Market Snapshot

About

Arcus Biosciences is a clinical-stage biopharmaceutical company developing innovative cancer immunotherapies. The company focuses on creating differentiated molecules that can work together to overcome immune suppression in the tumor microenvironment and improve patient outcomes in multiple cancer types.